Microbiome decoded, healthcare transformed
Enterome (enterome.com) earns a Brand Analyzer score of 77 out of 100, placing it in the Brand-Ready tier among Healthcare brands. Among 2685 Healthcare brands analyzed, Enterome ranks in the 83rd percentile (category average 70, leader 96). The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark. Dimension scores: Name Quality 98/100, Digital Presence 100/100, Visual Identity 93/100, Messaging Clarity 95/100, Trust Foundation 93/100, AI Discoverability 71/100, Brand Authority 11/100.
Enterome is a clinical-stage biopharmaceutical company headquartered in London, United Kingdom, founded in 2014. It specializes in decoding molecular interactions within the gut microbiome to develop novel cancer immunotherapies. Its lead technology, OncoMimics™, creates off-the-shelf treatments designed to overcome immune tolerance to self-antigens, targeting tumor types such as glioblastoma, adrenal tumors, non-Hodgkin lymphoma, and colorectal cancer. The company works with healthcare providers, clinical researchers, and industry partners to advance its pipeline of transformational drugs.
| Brand Name | Enterome |
|---|---|
| Domain | enterome.com |
| Industry | Healthcare |
| Founded | 2014 |
| Headquarters | London |
| Main Competitors | Seres Therapeutics (75/100), MaaT Pharma, Vedanta Biosciences (74/100), BiomX, Evelo Biosciences, Immatics, Gritstone bio |
Moz Domain Authority 36/100 vs category average 31 / leader 95 - a strong backlink profile, so AI systems frequently encounter mentions of the brand.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "We are a clinical stage biopharmaceutical company developing novel drugs to transform human health based on our unique ability to de-code molecular interactions in the gut microbio…" (Meta description: 27 words (ideal length). OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: 1 JSON-LD block(s), Breadcrumb/Website schema, og:title, og:description, og:type, Twitter cards, canonical. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: No robots.txt found (default: all bots allowed, but explicit file preferred) - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: PHP, Apache, WordPress, Ghost.
Social footprint: verified profiles on LinkedIn, YouTube, X (Twitter), Instagram, GitHub; no detected presence on Facebook - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Enterome scores 31/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Enterome has a weak AI-visibility profile at 31/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (45/100) and its weakest is visibility (21/100). It benefits from a Wikidata knowledge-graph entry and open access for AI crawlers (GPTBot, ClaudeBot, etc.). The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, a low Moz Domain Authority of 36/100 and thin schema.org structured data. In a live check, Claude could already identify Enterome from memory (August 2026) - a sign these signals are paying off.
Live results from asking a general-purpose AI assistant about the brand, checked August 2026.
When asked "What is Enterome?", Claude could identify the brand as of August 2026. Enterome is a French clinical-stage biotech company that develops drugs targeting the microbiome, particularly using its OncoMimics platform to create cancer immunotherapies and treatments for inflammatory diseases based on molecular mimicry between gut bacteria and disease-relat Best known for Developing microbiome-based OncoMimics cancer immunotherapies and IBD treatments derived from gut bacteria research.
When asked "Best brands similar to Enterome?", Claude would recommend Enterome as of August 2026. It's a notable player in microbiome-targeted therapeutics, a distinct niche worth mentioning for someone researching that specific biotech field.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Enterome's main competitors include Seres Therapeutics (75/100), MaaT Pharma, Vedanta Biosciences (74/100), BiomX, Evelo Biosciences. These companies compete in the Healthcare space for similar customers, offering comparable products or services.
Sources: Brand Analyzer scan
Enterome and Seres Therapeutics are competitors in Healthcare. Brand Analyzer scores Enterome at 77/100 and Seres Therapeutics at 75/100. They target overlapping audiences; the right choice depends on your specific needs and priorities.
Sources: Brand Analyzer scan
Popular alternatives to Enterome include Seres Therapeutics (75/100), MaaT Pharma, Vedanta Biosciences (74/100), BiomX, Evelo Biosciences. Each is an established option in the Healthcare space; the best fit depends on your specific needs, budget, and required features.
Sources: Brand Analyzer scan
Enterome's main offering is its OncoMimics™ platform, which produces off-the-shelf cancer immunotherapies. These therapies are being developed for tumor types such as glioblastoma, adrenal tumors, non-Hodgkin lymphoma, and colorectal cancer, and are based on decoding gut microbiome molecular interactions to generate immune responses against cancer antigens.
Sources: Enterome official site
Enterome is a clinical-stage biopharmaceutical company based in London, United Kingdom, founded in 2014. It focuses on developing novel drugs by decoding molecular interactions within the gut microbiome, with a primary emphasis on cancer immunotherapy.
Sources: Enterome official site
Enterome has limited AI-search visibility, scoring 31/100 on Brand Analyzer's AI visibility composite (visibility 21, trust 33, recommendation 45). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Enterome official site
Enterome was founded in 2014. Enterome operates in the Healthcare category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
Enterome is headquartered in London. Enterome operates in the Healthcare category.
Sources: Wikidata
Enterome develops cancer immunotherapies by analyzing molecular interactions in the gut microbiome. Its core technology, OncoMimics™, is used to design off-the-shelf treatments that generate strong, long-lasting immune responses by overcoming the body's natural immune tolerance to self-antigens. The company applies this approach to multiple tumor types, including glioblastoma, adrenal tumors, non-Hodgkin lymphoma, and colorectal cancer.
Sources: Enterome official site
Enterome scores 45/100 on Brand Analyzer's AI recommendation signal, indicating it is less likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: Enterome official site
Enterome is known for its OncoMimics™ platform, which uses gut microbiome-derived molecular mimicry to create cancer immunotherapies designed to break immune tolerance to self-antigens.
Sources: Enterome official site
Enterome can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Enterome official site
Enterome's therapies and research are intended for oncology patients with tumor types such as glioblastoma, adrenal tumors, non-Hodgkin lymphoma, and colorectal cancer. The company also collaborates with healthcare providers, clinical researchers, and pharmaceutical or biotech industry partners and investors.
Sources: Enterome official site
Ranked closest to Enterome: Eleos Health (77/100), Eitan Medical (77/100), eSkill (77/100), America's Essential Hospitals (77/100).
A step up - brands to learn from: Zurich Insurance Group (81/100), Zimmer Biomet (81/100).
Category leader: Elsevier (96/100).